A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
David P. Ryan(East Carolina University), James C. Cusack(Massachusetts General Hospital), Leonard J. Appleman(University of Pittsburgh), Elizabeth Claire Dees(University of North Carolina at Chapel Hill), Carlo M. Rocha Lima(University of Miami), Robert Z. Orlowski(University of North Carolina at Chapel Hill), Joseph P. Eder(Yale Cancer Center), Jeffrey W. Clark(Massachusetts General Hospital), Jeffrey G. Supko(Harvard University), Oscar Kashala(Millennium Engineering and Integration (United States)), Phinos Fidias(Massachusetts General Hospital), Bert H. O’Neil(Indiana University Health)
Cited by 66
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
|Nature|2014|2.4k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k